Premium
Letter: increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti‐TNFα agents, particularly etanercept, for autoimmune diseases other than IBD
Author(s) -
Dai Cong,
Jiang Min,
Sun MingJun
Publication year - 2019
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.15460
Subject(s) - medicine , ulcerative colitis , etanercept , inflammatory bowel disease , tumor necrosis factor alpha , inflammatory bowel diseases , crohn's disease , colitis , crohn disease , immunology , autoimmune disease , disease , gastroenterology , infliximab , dermatology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom